Evidence map›Paper›PMID 34785794›Full record

ArticleLeukemia2021

Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.

Elias K Mai, Kaya Miah, Uta Bertsch, Jan Dürig, Christof Scheid, Katja C Weisel, Christina Kunz, Markus Munder, Hans-Walter Lindemann, Maximilian Merz and 18 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Elias K MaiDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6226-1252
Kaya MiahDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Uta BertschDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Jan DürigDepartment of Hematology, University Clinic Essen, Essen, Germany.
Christof ScheidDepartment of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
Katja C WeiselDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christina KunzDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Markus MunderDepartment of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.
Hans-Walter LindemannDepartment of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany.
Maximilian MerzDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Dirk HoseDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Anna JauchInstitute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
Anja SeckingerDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Steffen LuntzCoordination Centre for Clinical Trials, University Hospital Heidelberg, Heidelberg, Germany.
Sandra SauerDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Stephan FuhrmannDepartment of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany.
Peter BrossartUniversity Hospital Bonn, Bonn, Germany.
Ahmet ElmaagacliDepartment of Hematology and Oncology, Asklepios Hospital Hamburg St. Georg, Hamburg, Germany.
Martin GoernerDepartment of Hematology, Oncology and Palliative Care, Klinikum Bielefeld, Bielefeld, Germany.
Helga BernhardDepartment of Internal Medicine V, Klinikum Darmstadt, Darmstadt, Germany.
Martin HoffmannMedical Clinic A, Klinikum Ludwigshafen, Ludwigshafen, Germany.
Marc S RaabDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Igor W BlauMedical Clinic, Charité University Medicine Berlin, Berlin, Germany.
Mathias HänelDepartment of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.
Axel BennerDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7238-6956
Hans J SalwenderDepartment of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.
Hartmut GoldschmidtDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. hartmut.goldschmidt@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-0961-0035
German-speaking Myeloma Multicenter Group (GMMG)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34785794
PMCPMC8632669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.